Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases Part 2

The long-term contraceptive of pantoprazole and rabeprazole appears similar to that of omeprazole and lansoprazole.
Pantoprazole, which is in the exam stages of approving for merchandising in the United States, will be available in both an oral and injectable expression.
Determination: Based on superordinate efficacy profiles, PPIs are the drugs of option in managing patients with peptic ulcer disease, gastroesophageal ebb disease, and Zollinger-Ellison complex.
The resolve to select one PPI versus another is most likely to be based on the agents’ acquiring costs, formulations, FDA-labeled indications, and work-clothes contraceptive profiles.
Intravenous or parenteral pantoprazole may become the preferred antisecretory bourgeois for patients unable to take oral medications (e.g., critically ill patients and those with Zollinger-Ellison syndrome).

IntroductionProton pump inhibitors (PPIs) represent the most important recent sum of money in the discussion of acid-related gastrointestinal (GI) diseases.
Based on efficacy profiles graphic symbol to those of histamine H2-receptor antagonists (H2RA), sucralfate, and cisapride, PPIs are now considered the drugs of decision making in managing patients with peptic ulcer disease (PUD), gastroesophageal flowing disease (GERD), and Zollinger-Ellison complex (ZES).
Currently, there are troika PPIs available in the United States: omeprazole (Prilosec — Astra Zeneca), lansoprazole (Prevacid — TAP Pharmaceuticals), and rabeprazole (Aciphex — Janssen Pharmaceutica).
This is a part of article Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-Related Diseases Part 2 Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog